<DOC>
	<DOCNO>NCT02537938</DOCNO>
	<brief_summary>This study involve use investigational drug call NGP 555 . In group healthy subject , 2 people receive placebo 6 people receive NGP 555 .</brief_summary>
	<brief_title>Neurogenetic Pharmaceuticals ( NGP ) 555 Healthy Volunteers ( 14 Day Multiple Ascending Dose )</brief_title>
	<detailed_description>The purpose research study determine safety , tolerability , pharmacokinetics ( PK ) multiple ( 14 day ) , oral dos NGP 555 healthy volunteer . NGP 555 create treatment Alzheimer 's disease ( AD ) . NGP 555 develop prevent Abeta 42 amyloid formation , protein likely key factor development AD .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Male female volunteer age 4065 yrs good health determine medical history , physical examination , clinical laboratory study , electrocardiogram ( ECGs ) , vital sign , investigator judgement 2 . Volunteer voluntarily agree participate study sign Institutional Review Board ( IRB ) approve informed consent prior perform screen procedure 3 . Female volunteer postmenopausal surgically sterile 4 . Female volunteer childbearing potential must agree use medically acceptable method contraception 5 . Male healthy volunteer willing use barrier contraception ( i.e. , condom ) even partner postmenopausal , surgically sterile use acceptable contraceptive method 6 . Body mass index ( BMI ) ≥ 18.0 kg/m2 ≤ 32.0 kg/m2 1 . Personal history seizure disorder , symptomatic seizure ( include history simple febrile seizure childhood ) past present medical condition , opinion investigator potential reduce seizure threshold ( e.g. , history head trauma concussion , previous alcohol abuse , substance abuse ) 2 . Any concurrent disease condition , opinion Investigator , would make volunteer unsuitable participation clinical study 3 . Volunteer history alcohol and/or illicit drug abuse within two year entry 4 . Any psychiatric diagnosis symptom ( e.g. , hallucination , major depression , anxiety delusion ) 5 . History cerebrovascular event nonvasovagal related loss consciousness 6 . History cardiac arrhythmia , ischemic heart disease , cerebrovascular disease . 7 . Hepatic impairment define &gt; 1.3 time upper limit normal range serum liver enzymes 8 . Renal impairment define &gt; 1.3 abnormal range serum creatinine 9 . Abnormal blood pressure 10 . Abnormal cardiovascular parameter 11 . Volunteers abnormally low serum B12 , folate abnormal thyroid function test 12 . Positive Screening test Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody 13 . Positive urine test alcohol drug 14 . Any suicidal behavior last 2 year 15 . Female volunteer breastfeed female volunteer positive urine pregnancy test 16 . Volunteers unwilling avoid consumption coffee caffeine contain beverage 17 . Unable abstain smoking ( nicotine use ) 18 . Donation blood ( &gt; 500 mL ) blood product within 2 month 19 . Volunteers take prohibit medication 20 . Use investigational drug within 30 day prior Screening ( Visit 1 ) 21 . Unwilling abstain vigorous exercise 22 . Clinically significant deviation normal physical examination , vital sign clinical laboratory test 23 . Volunteer unable understand protocol requirement , instruction studyrelated restriction , nature , scope possible consequence clinical study 24 . Volunteer unlikely comply protocol requirement , instruction studyrelated restriction ( e.g. , uncooperative attitude , inability return followup visit improbability complete clinical study ) 25 . Volunteer medical condition unstable , clinical opinion Investigator , may interfere study procedure volunteer safety . Volunteers follow stable medical condition , adequately control stable dos concomitant medication , need exclude opinion Investigator , condition compromise volunteer safety study procedure :</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>